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ear Editor,
ecurrent peritonitis due to a suspected bioﬁlm causes sub-
tantial morbidity in patients with peritoneal dialysis (PD)
nd sometimes leads to permanent abandonment of the tech-
ique.
We  present the case of a 55-year-old man  with a prior his-
ory of meningitis due to listeria, resolved with antibiotic treat-
ent, chronic kidney disease (CKD) secondary to membra-
ous glomerulonephritis in PD and an adrenal incidentaloma.
He visited our department owing to signs and symptoms
f peritonitis due to clinically asymptomatic Staphylococcus epi-
ermidis, which resolved with intraperitoneal (IP) vancomycin
dministered for 14 days. The post-treatment monitoring cul-
ure was negative.
Fifteen days after completion of antibiotic therapy, he had
 recurrence of peritonitis caused by the same microorgan-
sm, and then he was treated with oral ciproﬂoxacin adjusted
o antibiogram results without achieving a negative periton-
al ﬂuid culture. Given the suspicion of recurring peritonitis
ue to a bioﬁlm, intravenous (IV) daptomycin was started
t a dose of 500 mg/48 h (residual diuresis 400 ml/24 h). After
0 days of treatment, the ﬂuid remained slightly cloudy
220 cells/l,  55% polymorphonuclear cells, 45% monomor-
honuclear cells), with a positive culture for S. epidermidis.
herefore, treatment was started with IP daptomycin (200 mg
oading dose followed by 40 mg in each exchange) and main-
ained for 14 days. Throughout this time, the patient received
ssociated antifungal prophylaxis.
The peritoneal ﬂuid culture during and after treatment was
egative.
After completing intraperitoneal antibiotic treatment, the
atient resumed his usual therapy (automatic PD with a
aytime exchange). He was scheduled for daptomycin lseal
herapy, administered once per week for 4 weeks.
The sealing therapy protocol was performed using 35 mg
f daptomycin in 7 ml  of lactated Ringer’s solution, with the
bdomen empty for a minimum of 12 h.
Currently, the patient remains asymptomatic, and has had
o more  episodes of peritonitis.
Daptomycin is a lipopeptide antibiotic indicated in the
reatment of bacteraemia, right-sided endocarditis and com-
licated skin infections, with anti-bioﬁlm activity.1Several cases of treatment of peritonitis in PD with both IV
nd IP daptomycin have been reported.
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Goedecke et al. showed that intravenous administration
of daptomycin achieved plasma and peritoneal ﬂuid lev-
els greater than the minimum inhibitory concentration for
microorganisms sensitive to this antibiotic. However, the
study was conducted in a single patient.2
Subsequently, several cases were reported of peritonitis in
PD that were successfully treated with IV daptomycin.3,4A study of the pharmacokinetics of daptomycin in PD, with
the dual aim of evaluating the drug’s penetration of the perit-
oneal cavity and obtaining a dose regimen to be administered
in this type of patients that offered safety and prevented toxic-
ity, concluded that administration at doses of 4–6 mg/kg/48 h is
an appropriate regimen for treating non-peritoneal systemic
infections in patients who receive continuous ambulatory PD
but, owing to its limited penetration of the abdominal cavity,
its administration by the IV route is not safe for the treatment
of peritonitis.5
In the case presented, daptomycin administered by the
intravenous route did not achieve a negative peritoneal
ﬂuid culture. At the time of administration, peritoneal
inﬂammation was not substantial, and the percentage of poly-
morphonuclear cells was only 55%, given that the patient
was undergoing antibiotic treatment with ciproﬂoxacin, and
the even lower penetration in the abdominal cavity could be
attributed to this. Although there have been no studies on
how peritoneal inﬂammation inﬂuences the concentration of
daptomycin in the peritoneum, a study by Cardone et al.5
suggested that the peritoneal inﬂammation that occurs in
the patients studied should to a certain extent promote the
drug’s penetration of the peritoneal cavity, without being able
to ensure whether suitable levels would be achieved as the
inﬂammatory process decreases.
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Dear Editor:
Androgen deﬁciency is an endocrine abnormality that is
common in male patients with chronic kidney disease and
affects 50%–75% of patients treated with haemodialysis.1,2 Its
clinical signiﬁcance is not well known, although various cross-
sectional studies have linked low testosterone levels to sexual
dysfunction, anaemia, loss of muscle mass, increase in car-
diovascular risk and greater mortality.2–5
Androgens in pharmacological doses have effects on
anaemia and nutritional parameters in patients treated with
regular haemodialysis.6 However, few studies have analysed
the effect of treating hypogonadism from renal failure with
physiological doses of testosterone, and their results have
been controversial.7,8
In this study we  present the preliminary data for the
results obtained following correction of androgen deﬁciency
in patients treated with haemodialysis.
We deﬁned androgen deﬁciency as a total serum testos-
terone concentration lower than 300 ng/dl and an unbound
testosterone concentration lower than 225 pMol/l. Testos-
terone circulates in plasma bound to proteins (especially
albumin and a transport globulin [sex hormone-binding glob-
ulin, or SHBG]); only 1%–3% circulates unbound. A uraemic
patient may have an abnormal SHBG concentration.9 There-
fore, in patients with chronic kidney disease it is advisable to
conﬁrm testosterone deﬁciency by determining the concen-
tration of unbound testosterone, especially in cases with a
total testosterone level that is low but close to the lower limit of
the normal range. Unbound testosterone was calculated based
10on levels of total testosterone, SHBG and albumin.
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The study was conducted in male patients treated with
regular haemodialysis for more  than 6 months who  were in
a stable clinical situation and had not required admission in
the last 3 months. All draws for laboratory testing were per-
formed immediately before the ﬁrst haemodialysis session of
the week.
Of the 39 patients analysed, 20 (51%) had a total testos-
terone concentration lower than 300 ng/dl, all had an unbound
testosterone concentration lower than 225 pMol/l, and all
were diagnosed with androgen deﬁciency. Twelve of these
20 patients agreed to participate in the study and granted
their written consent. Patients were randomly assigned to the
treatment group (6 patients who received testosterone by the
transdermal route: one sachet of 5 g of gel containing 50 mg
of testosterone daily for 3 months) or the control group (the
other 6 patients). The dose of testosterone administered to the
treatment group was the minimum initial dose recommended
in the medicine’s summary of product characteristics.
Patients in the treatment group had a younger age (67 ± 4
vs 75 ± 9 years; p = 0.182), and at baseline there were no
differences between the two groups in terms of the other
parameters analysed. Table 1 shows the changes in these
parameters. The unbound and total serum testosterone con-
centration increased in all patients treated, but it only reached
the normal range in 4 (Fig. 1). Neither of the 2 groups of patients
showed a change in concentrations of total cholesterol, HDL
cholesterol, LDL cholesterol or triglycerides (data not shown).
The prevalence of androgen deﬁciency in male patients
from the haemodialysis unit was 51%. This ﬁgure was similar
to that observed in other studies. Transdermal administra-ez Lucas M, Delgado Yagüe M, García Cano AM,  Lian˜o García F.
plementos de testosterona. Resultados preliminares. Nefrologia.
tion of testosterone, in the minimum dose recommended in
